Ousmane TRAORE

Placental malaria (PM) poses significant health risks, including maternal anaemia, premature delivery, and low birth weight. Early detection of PM is challenging due to the lack of reliable diagnostic methods during
pregnancy. Recent studies suggest that certain immunological biomarkers, such as IL-10, sTNF-RII,
antibodies to DBL5, C5a, and VEGF, could serve as early indicators of PM.

Objectives:

Primary Objectives:
Evaluate Biomarkers: Assess the precision and reliability of identified biomarkers (IL-10, sTNF-RII, antibodies to DBL5, C5a, and VEGF) in detecting PM during pregnancy.

Develop a Diagnostic Platform: Use evaluation data to develop an ELISA-based diagnostic platform incorporating the most accurate biomarker data.

Secondary Objectives:

Stage-Specific Reliability: Investigate how the effectiveness of biomarkers varies across pregnancy stages.

Intervention Integration: Combine biomarker findings with existing intervention strategies.

Stratified Analysis: Enhance precision in detecting biomarker variations across different anti-malarial
treatments.

Study Design:
Conducted in Burkina Faso, the study will involve 100 pregnant women (50 with PM and 50 without). Plasma samples will be collected at days 0, 28, and 63 to validate biomarker accuracy. The study aims to develop a reliable diagnostic tool for early PM detection, improving maternal and infant health outcomes in malaria-endemic areas.

GSK Africa Open Lab

Septembre 01, 2024

June 30, 2027

Infectious Diseases (Malaria, HIV/AIDS, TB, NTDs)